Cargando…

Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner

The innate immune response to cytosolic DNA involves transcriptional activation of type I interferons (IFN-I) and proinflammatory cytokines. This represents the culmination of intracellular signaling pathways that are initiated by pattern recognition receptors that engage DNA and require the adaptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Jinu, Botto, Sara, Mizuno, Nobuyo, Pryke, Kara, Gall, Bryan, Boehm, Dylan, Sali, Tina M., Jin, Haihong, Nilsen, Aaron, Gough, Michael, Baird, Jason, Chakhtoura, Marita, Subra, Caroline, Trautmann, Lydie, Haddad, Elias K., DeFilippis, Victor R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360819/
https://www.ncbi.nlm.nih.gov/pubmed/32733475
http://dx.doi.org/10.3389/fimmu.2020.01430
_version_ 1783559287993270272
author Abraham, Jinu
Botto, Sara
Mizuno, Nobuyo
Pryke, Kara
Gall, Bryan
Boehm, Dylan
Sali, Tina M.
Jin, Haihong
Nilsen, Aaron
Gough, Michael
Baird, Jason
Chakhtoura, Marita
Subra, Caroline
Trautmann, Lydie
Haddad, Elias K.
DeFilippis, Victor R.
author_facet Abraham, Jinu
Botto, Sara
Mizuno, Nobuyo
Pryke, Kara
Gall, Bryan
Boehm, Dylan
Sali, Tina M.
Jin, Haihong
Nilsen, Aaron
Gough, Michael
Baird, Jason
Chakhtoura, Marita
Subra, Caroline
Trautmann, Lydie
Haddad, Elias K.
DeFilippis, Victor R.
author_sort Abraham, Jinu
collection PubMed
description The innate immune response to cytosolic DNA involves transcriptional activation of type I interferons (IFN-I) and proinflammatory cytokines. This represents the culmination of intracellular signaling pathways that are initiated by pattern recognition receptors that engage DNA and require the adaptor protein Stimulator of Interferon Genes (STING). These responses lead to the generation of cellular and tissue states that impair microbial replication and facilitate the establishment of long-lived, antigen-specific adaptive immunity. Ultimately this can lead to immune-mediated protection from infection but also to the cytotoxic T cell-mediated clearance of tumor cells. Intriguingly, pharmacologic activation of STING-dependent phenotypes is known to enhance both vaccine-associated immunogenicity and immune-based anti-tumor therapies. Unfortunately, the STING protein exists as multiple variant forms in the human population that exhibit differences in their reactivity to chemical stimuli and in the intensity of molecular signaling they induce. In light of this, STING-targeting drug discovery efforts require an accounting of protein variant-specific activity. Herein we describe a small molecule termed M04 that behaves as a novel agonist of human STING. Importantly, we find that the molecule exhibits a differential ability to activate STING based on the allelic variant examined. Furthermore, while M04 is inactive in mice, expression of human STING in mouse cells rescues reactivity to the compound. Using primary human cells in ex vivo assays we were also able to show that M04 is capable of simulating innate responses important for adaptive immune activation such as cytokine secretion, dendritic cell maturation, and T cell cross-priming. Collectively, this work demonstrates the conceivable utility of a novel agonist of human STING both as a research tool for exploring STING biology and as an immune potentiating molecule.
format Online
Article
Text
id pubmed-7360819
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73608192020-07-29 Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner Abraham, Jinu Botto, Sara Mizuno, Nobuyo Pryke, Kara Gall, Bryan Boehm, Dylan Sali, Tina M. Jin, Haihong Nilsen, Aaron Gough, Michael Baird, Jason Chakhtoura, Marita Subra, Caroline Trautmann, Lydie Haddad, Elias K. DeFilippis, Victor R. Front Immunol Immunology The innate immune response to cytosolic DNA involves transcriptional activation of type I interferons (IFN-I) and proinflammatory cytokines. This represents the culmination of intracellular signaling pathways that are initiated by pattern recognition receptors that engage DNA and require the adaptor protein Stimulator of Interferon Genes (STING). These responses lead to the generation of cellular and tissue states that impair microbial replication and facilitate the establishment of long-lived, antigen-specific adaptive immunity. Ultimately this can lead to immune-mediated protection from infection but also to the cytotoxic T cell-mediated clearance of tumor cells. Intriguingly, pharmacologic activation of STING-dependent phenotypes is known to enhance both vaccine-associated immunogenicity and immune-based anti-tumor therapies. Unfortunately, the STING protein exists as multiple variant forms in the human population that exhibit differences in their reactivity to chemical stimuli and in the intensity of molecular signaling they induce. In light of this, STING-targeting drug discovery efforts require an accounting of protein variant-specific activity. Herein we describe a small molecule termed M04 that behaves as a novel agonist of human STING. Importantly, we find that the molecule exhibits a differential ability to activate STING based on the allelic variant examined. Furthermore, while M04 is inactive in mice, expression of human STING in mouse cells rescues reactivity to the compound. Using primary human cells in ex vivo assays we were also able to show that M04 is capable of simulating innate responses important for adaptive immune activation such as cytokine secretion, dendritic cell maturation, and T cell cross-priming. Collectively, this work demonstrates the conceivable utility of a novel agonist of human STING both as a research tool for exploring STING biology and as an immune potentiating molecule. Frontiers Media S.A. 2020-07-08 /pmc/articles/PMC7360819/ /pubmed/32733475 http://dx.doi.org/10.3389/fimmu.2020.01430 Text en Copyright © 2020 Abraham, Botto, Mizuno, Pryke, Gall, Boehm, Sali, Jin, Nilsen, Gough, Baird, Chakhtoura, Subra, Trautmann, Haddad and DeFilippis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Abraham, Jinu
Botto, Sara
Mizuno, Nobuyo
Pryke, Kara
Gall, Bryan
Boehm, Dylan
Sali, Tina M.
Jin, Haihong
Nilsen, Aaron
Gough, Michael
Baird, Jason
Chakhtoura, Marita
Subra, Caroline
Trautmann, Lydie
Haddad, Elias K.
DeFilippis, Victor R.
Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner
title Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner
title_full Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner
title_fullStr Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner
title_full_unstemmed Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner
title_short Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner
title_sort characterization of a novel compound that stimulates sting-mediated innate immune activity in an allele-specific manner
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360819/
https://www.ncbi.nlm.nih.gov/pubmed/32733475
http://dx.doi.org/10.3389/fimmu.2020.01430
work_keys_str_mv AT abrahamjinu characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT bottosara characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT mizunonobuyo characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT prykekara characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT gallbryan characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT boehmdylan characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT salitinam characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT jinhaihong characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT nilsenaaron characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT goughmichael characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT bairdjason characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT chakhtouramarita characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT subracaroline characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT trautmannlydie characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT haddadeliask characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner
AT defilippisvictorr characterizationofanovelcompoundthatstimulatesstingmediatedinnateimmuneactivityinanallelespecificmanner